Fresenius Medical Care AG
No SEC Form 4 filings for $FMS in the last 30 days.
See all $FMS insider activity →Fresenius Medical Care recalled 1,140 hemodialysis machines (models 191126 and 191130) due to flow, no-water, and temperature alarms. The FDA classified it as Class II, indicating temporary or reversible harm. Clinics must use backup machines until parts are replaced, potentially disrupting schedules.
Fresenius Medical Care AG repurchased 705,000 shares from August 17 to 21, 2026, as part of its first tranche of a share buyback program. The company has acquired a total of 5,856,274 shares in this tranche. The buyback is being executed by a commissioned credit institution. Regular updates will be posted on the company's investor relations page.
Fresenius Medical Care AG reported interim results of its first tranche share buyback. From Aug 10 to Aug 14, 2026, it bought back 722,500 shares at weighted average prices around EUR 41.06 to EUR 42.36, totaling EUR 30.65m. A total of 5,151,274 shares have been acquired so far, via a commissioned credit institution.
Over the past 7 days, alphai's AI scored 2 news stories mentioning FMS (Fresenius Medical Care AG). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent FMS coverage spans earnings, market movers and corporate actions.
Recall may pressure Fresenius Medical Care stock due to potential clinic disruptions and replacement costs.
The buyback signals confidence and may support the stock price in the short term.
The update is a routine buyback tranche disclosure, likely supportive at the margin but not a major fundamental reset.
Operational execution improved via Care Delivery margin expansion and transformation savings, but U.S. referral capture and China regulatory headwinds remain drags.
Price action suggests earnings-related optimism, but the excerpt does not disclose the earnings catalyst.
alphai scores every news story that mentions FMS with an AI model for sentiment and relevance, and aggregates insider trades from Fresenius Medical Care AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Fresenius Medical Care recalled 1,140 hemodialysis machines (models 191126 and 191130) due to flow, no-water, and temperature alarms. The FDA classified it as Class II, indicating temporary or reversible harm. Clinics must use backup machines until parts are replaced, potentially disrupting schedules.
2 min readFresenius Medical Care AG repurchased 705,000 shares from August 17 to 21, 2026, as part of its first tranche of a share buyback program. The company has acquired a total of 5,856,274 shares in this tranche. The buyback is being executed by a commissioned credit institution. Regular updates will be posted on the company's investor relations page.
2 min readFresenius Medical Care AG reported interim results of its first tranche share buyback. From Aug 10 to Aug 14, 2026, it bought back 722,500 shares at weighted average prices around EUR 41.06 to EUR 42.36, totaling EUR 30.65m. A total of 5,151,274 shares have been acquired so far, via a commissioned credit institution.
2 min readFresenius Medical Care (FMS) reported Q2 2026 revenue of EUR 4,861 million, up 5% organically, and adjusted operating income of EUR 569 million (+23% at constant currency). Adjusted basic EPS was EUR 1.13 (+28% constant currency). Management reaffirmed broadly flat 2026 revenue and operating income growth, citing U.S. referral execution issues and China regulatory headwinds.
6 min readGermany’s DAX rose modestly in Thursday morning trading, reaching 26,210.50 before easing to 26,169.49 (+0.12%). Deutsche Telekom gained about 6% on Q2 operating profit of €6.863bn and a larger 2026 buyback. Merck rose 1.5% after upgrading full-year guidance. Other moves included Henkel (+4.3%) and Siemens (-6%).
4 min readEuropean stocks closed higher on Tuesday. The pan-European Stoxx 600 rose 0.73%, with DAX up 0.77% and CAC 40 up 0.61%. Brent crude fell nearly 6% to $78.70. Company moves included Travis Perkins +18.5% on strong interim results, Smith & Nephew -6% after cutting its forecast, and Zalando -13.4% after lowering its 2026 outlook. HSBC reported $14.626B net income and announced a share buyback.
6 min readFresenius Medical Care (NYSE:FMS) reported Q2 call highlights, including clinic closures of about 100 underperforming sites and rollout of high-volume hemodiafiltration. The company said U.S. same-market treatment growth for 2026 should stay around Q2 levels due to lower referrals. Care Delivery operating income rose 45% and FCF was EUR 625 million. It expects TDAPA to be a EUR 50 million full-year headwind and is buying back shares under a EUR 1 billion program.
6 min readGerman stocks rose for a fourth straight session, with the DAX hitting a record 26,267.62 before easing to 26,154.75 (+0.45%). Gains were supported by upbeat earnings and a U.S. ISM manufacturing PMI jump to 55.6. Bayer, Rheinmetall, and Infineon rose. Zalando cut its 2026 outlook, Fresenius Medical Care fell, and Lufthansa dropped on lower profit guidance.
4 min readFresenius Medical Care shares fell 8.0% to about €41.29 after its Q2 2026 results. The company reported operating income excluding special items of €569 million and revenue of €4.861 billion, both above consensus, but U.S. same-market treatment volumes declined about 0.9% YoY. Analysts cited unchanged guidance and volume risk, reiterating lower price targets.
5 min readFresenius Medical Care reported Q2 2026 organic revenue growth of 5% and operating income up 23% to a margin of 11.7%. Reported operating income rose 10%, while net income fell 3%. EPS increased 28% supported by share buybacks. The company said 227 U.S. clinics converted to its 5008X CAREsystem with 600,000+ treatments and reaffirmed its FY 2026 outlook.
5 min read
